MTOR and neoplasm: Although rapamycin and its analogues (rapalogs) have shown clinical efficacy in a subset of cancer types, they do not fully exploit the potential anti-tumor activity of the mTOR-targeting drugs, to some extent because of their pharmacodynamics.